Journal of Headache and Pain

Papers
(The H4-Index of Journal of Headache and Pain is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019473
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates369
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update200
Migraine and neuroinflammation: the inflammasome perspective132
Comorbidities of primary headache disorders: a literature review with meta-analysis97
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)91
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs79
Long COVID headache78
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace73
Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials73
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects68
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine68
Applying a biopsychosocial model to migraine: rationale and clinical implications60
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months59
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism54
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients53
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)52
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis50
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study44
Medication overuse and drug addiction: a narrative review from addiction perspective43
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance43
Association between response to triptans and response to erenumab: real-life data42
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine42
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis41
Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 202040
Inflammatory complications of CGRP monoclonal antibodies: a case series40
Differential alteration of fMRI signal variability in the ascending trigeminal somatosensory and pain modulatory pathways in migraine38
Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients38
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study38
Is there a causal relationship between stress and migraine? Current evidence and implications for management37
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension37
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description37
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study36
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes36
Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study36
Concurrent brain structural and functional alterations in patients with migraine without aura: an fMRI study35
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine35
0.92131996154785